Author:
Yang Li,Shen MingJing,Xu Li Jun,Yang Xiaodong,Tsai Ying,Keng Peter C.,Chen Yuhchyau,Lee Soo Ok
Abstract
Abstract
Major progress has been made clinically in inhibiting the programmed death receptor 1 (PD-1)/PD-L1 interaction to enhance T cell-mediated immune function, yet the effectiveness of anti-PD-L1/PD-1 agents in enhancing natural killer (NK) cell’s function remains largely unknown. Susceptibilities of cisplatin-resistant A549CisR and H157CisR cells vs. parental cells to the cytotoxic action of NK cells were examined. We found cisplatin-resistant cells more resistant to NK cell cytotoxicity than parental cells. There were constitutively higher expressions of PD-L1 in A549CisR and H157CisR cells than in parental cells in vitro, as well as in H157CisR cell-derived tumors than H157P cell-derived tumors. In contrast, we observed that the expression of PD-1 in NK cells was induced after co-culture with cisplatin-resistant cells. We also observed increased susceptibility of cisplatin-resistant cells to NK cell cytotoxicity when neutralizing antibody of PD-1 or PD-L1 was added. Further, we found that the NK group 2, member D (NKG2D) ligand levels were lower in A549CisR and H157CisR cells than in parental cells. Meanwhile, we discovered that the MEK/Erk signaling pathway played a significant role in this regulation, and the addition of a MEK/Erk pathway inhibitor significantly enhanced the PD-L1 Ab effect in enhancing NK cell cytotoxicity to cisplatin-resistant cells.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Reinmuth, N. & Reck, M. Immunotherapy for Lung Cancer. Oncology research and treatment 39, 360–368, doi:
10.1159/000446726
(2016).
2. Santarpia, M. et al. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert review of respiratory medicine 1–18, doi:
10.1080/17476348.2016.1182866
(2016).
3. Bagley, S. J., Bauml, J. M. & Langer, C. J. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. Clinical advances in hematology & oncology: H&O 13, 676–683 (2015).
4. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine 366, 2455–2465, doi:
10.1056/NEJMoa1200694
(2012).
5. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567, doi:
10.1038/nature14011
(2014).
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献